Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Conditions
- Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RefractoryLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Interventions
- Drug: intrathecal chemotherapy
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Princess Maxima Center for Pediatric Oncology
- Target Recruit Count
- 26
- Registration Number
- NCT05745714
- Locations
- 🇳🇱
Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients with AML
- Conditions
- Acute Myeloid LeukemiaMixed Lineage Acute LeukemiaMixed Lineage Leukemia Gene MutationMixed Phenotype Acute LeukemiaRefractory AMLAML with Mutated NPM1Acute Myeloid Leukemia RecurrentAcute Myeloid Leukemia, in RelapseNPM1 MutationKMT2Ar
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 212
- Registration Number
- NCT05735184
- Locations
- 🇺🇸
Moores UC San Diego Cancer Center, La Jolla, California, United States
🇺🇸USC University of Southern California / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA - Bowyer Oncology Center, Los Angeles, California, United States
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia
- Interventions
- Drug: Granulocyte Colony-Stimulating Factor
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Shanxi Bethune Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05726110
- Locations
- 🇨🇳
Tao Wang, Taiyuan, Shanxi, China
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukaemia
- Interventions
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 7
- Registration Number
- NCT05712278
- Locations
- 🇺🇸
~MD Anderson Cancer Center Site Number : 8400002, Houston, Texas, United States
🇺🇸University of Nebraska Medical Center Site Number : 8400003, Omaha, Nebraska, United States
🇺🇸Albert Einstein College of Medicine Site Number : 8400001, Bronx, New York, United States
Natural Killer(NK) Cell Therapy in r/r AML
- Conditions
- AML, Adult
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2023-01-03
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 18
- Registration Number
- NCT05665114
- Locations
- 🇨🇳
The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China
Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia
- Conditions
- AML, Adult
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2023-01-03
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 19
- Registration Number
- NCT05665075
- Locations
- 🇨🇳
The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China
HEM ISMART-D: Trametinib + Dexamethasone + Chemotherapy in Children with Relapsed or Refractory Hematological Malignancies
- Conditions
- Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RefractoryLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RefractoryLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
- Interventions
- Drug: Intrathecal chemotherapy
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Princess Maxima Center for Pediatric Oncology
- Target Recruit Count
- 26
- Registration Number
- NCT05658640
- Locations
- 🇦🇹
St. Anna Kinderspital, Vienna, Austria
🇧🇪Universitair Ziekenhuis Gent, Gent, Belgium
🇩🇰Rigshospitalet Copenhagen, Copenhagen, Denmark
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Interventions
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2023-03-03
- Target Recruit Count
- 100
- Registration Number
- NCT05660473
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms
- Conditions
- Myeloid Neoplasm
- Interventions
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT05656248
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT05645718
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.